Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731536 | 1.00 | PPARG (0.60) | PPARGNPC1ALDH1A1RAB9ACYP11B1 | |
| SCHEMBL16731548 | 0.92 | NPC1 (0.52) | PPARGNPC1ALDH1A1RAB9ACYP11B1 | |
| SCHEMBL16731549 | 0.91 | PPARG (0.61) | PPARGCYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL16731541 | 0.91 | PPARG (0.61) | PPARGCYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL16731550 | 0.91 | PPARG (0.61) | PPARGCYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL16713357 | 0.90 | PPARG (0.57) | PPARG | |
| SCHEMBL16713358 | 0.90 | PPARG (0.57) | PPARG | |
| SCHEMBL15992322 | 0.89 | PPARG (0.66) | PPARGNPC1ALDH1A1RAB9AHDAC1 | |
| SCHEMBL16731543 | 0.88 | NPC1 (0.59) | PPARGNPC1ALDH1A1RAB9ACYP11B1 | |
| SCHEMBL16731540 | 0.83 | PPARG (0.52) | PPARGNPC1RAB9ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309227-B2 | N-biphenylmethylbenzimidazole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150141464-A1 | N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141464-A1 | N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG | CDK5, PPARG, CDK5R1 | PPARG 2/4885NPC1 2554/4885ALDH1A1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.